Host factors and failure of interferon-alpha treatment in hepatitis C virus.
about
Hepatic steatosis: a benign disease or a silent killerProgrammed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapyAutophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseasesDissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell lineActivation of anti-hepatitis C virus responses via Toll-like receptor 7.Association of pretreatment serum interferon inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis CNon-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In VitroReduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus repliconUsing high-throughput genomics to study hepatitis C: What determines the outcome of infection?Targeting host factors: A novel rationale for the management of hepatitis C virusThe Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon TherapyComparative Proteomics Reveals Important Viral-Host Interactions in HCV-Infected Human Liver CellsInterleukin28B and inosine triphosphatase help to personalize hepatitis C treatment.Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysisSH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells.IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control studyQuantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b.Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patientsIntracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication.Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro.Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan.Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionThe impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese ChineseAn overview of HCV molecular biology, replication and immune responses.A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infectionMutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong populationNew treatments for chronic hepatitis C.New hopes for HIV and HCV coinfection in 2004.The impact of host factors on management of hepatitis C virus.Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotypeAntiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks.Cytokine/chemokine patterns connect host and viral characteristics with clinics during chronic hepatitis C.Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapyHepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases.Liver diseases in the elderly: an update.Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon.
P2860
Q22305506-0ADC7ABD-5F8C-4E7A-A31F-B013191FD0EAQ26781481-954A9D26-BB14-43C6-83E2-2C0FAAF127E4Q26992256-89BC352A-7753-4F1F-BD91-35176D82FF7EQ27472675-13773AA5-ADF1-47CB-BC2C-A7651B79707FQ27473105-44812120-B934-4B2D-8B87-CA227BC822D0Q27478305-485AC21E-C770-4D90-B96D-6E1C0D31F21AQ27478313-F2FBCB29-6700-4B5F-8B0C-F10FE31E2E7BQ27480361-4386D2EA-DCBC-4B6C-9667-55C91F5A5CEFQ27481650-F8AB51A6-75C4-4FFD-9B9F-F24CEE79F46EQ27488407-3903A256-7EBE-482E-8E08-FDD51010BA47Q27488999-7626E968-9C41-4415-A3DB-ED26AF9FB56BQ27489040-506FEED0-2F89-4F67-A074-95618BB8760CQ28115022-2B8AFD54-D61F-485E-A005-CA444E1F594DQ33398664-5360CF53-1D12-4FCA-980B-FDC4EA1F0993Q33712188-1F79EA8B-D678-494F-B077-8C967CD2167AQ33719537-E0936D9B-9E57-4DFC-8D3F-230F064E1836Q33737419-7C98F6F7-B5D5-4BE6-8296-2AF6FB3231F4Q33903850-2941AE68-3532-433F-BC59-4D7677F949A2Q34079153-46E6DE22-4E8C-4C42-98ED-465C2FA96583Q34157284-2401DCBF-D8A7-4A01-8DE4-D139730311A9Q34243927-097BC68F-DD23-4667-8566-23E78BC712E3Q34365617-DDA11DB5-26D6-4660-BCC2-BC2BBFB47AD8Q34428880-1A12B5A3-DB1E-4EE2-856A-4E91D8D6038FQ34484305-A3F9F470-676E-4EBF-8C56-3DD4E400B8DBQ34599847-0107E780-46B9-477D-A9CB-6CEB3BC90671Q34709019-3EA709C5-03B1-4831-87AB-1FE08E777627Q34916120-A7C2FC96-4D70-4E51-819A-D4574B4CFA17Q35579175-9D58712E-7F84-40A1-9624-969EFCDEB5C1Q35612409-9C2784A1-3E1A-44CD-87D3-3AC2362EE027Q35638812-0BC1C306-53FA-4DF1-8729-355E2FE9CC0EQ35833006-66C218B3-A591-4F22-B7F7-4E67B94A00E7Q35912407-5DBB42A3-4350-4569-AC82-9A7C043A4CD5Q35990066-44263F29-6627-41C7-82CB-FFBE82E7DB87Q36226495-3CAD3933-BDD7-470E-B068-86ABD11A6751Q36240367-6582BFE8-0FC9-43A4-A64B-7E6D574C2259Q36373301-FBE64D89-B72E-48AE-8193-41F4D6C4AF84Q36383353-8CF9A1B4-002E-4628-845E-FB70963D5776Q36395865-19E8D705-7E84-4DE1-B189-1A4A22A59914Q36806271-62F49582-FDBD-4FB5-A7B4-2AD440D0206CQ37000796-7A68A11F-6A68-4A84-AB39-730F97B6C3B7
P2860
Host factors and failure of interferon-alpha treatment in hepatitis C virus.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Host factors and failure of interferon-alpha treatment in hepatitis C virus.
@ast
Host factors and failure of interferon-alpha treatment in hepatitis C virus.
@en
type
label
Host factors and failure of interferon-alpha treatment in hepatitis C virus.
@ast
Host factors and failure of interferon-alpha treatment in hepatitis C virus.
@en
prefLabel
Host factors and failure of interferon-alpha treatment in hepatitis C virus.
@ast
Host factors and failure of interferon-alpha treatment in hepatitis C virus.
@en
P2093
P2860
P356
P1433
P1476
Host factors and failure of interferon-alpha treatment in hepatitis C virus.
@en
P2093
Svetlana Radaeva
P2860
P304
P356
10.1002/HEP.20139
P407
P577
2004-04-01T00:00:00Z